Citigroup’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $104K | Buy |
22,468
+173
| +0.8% | +$448 | ﹤0.01% | 4664 |
|
|
2026
Q1 | $62.2K | Buy |
22,295
+11,070
| +99% | +$33.7K | ﹤0.01% | 4438 |
|
|
2025
Q4 | $46.7K | Buy |
11,225
+11,089
| +8,154% | +$58.4K | ﹤0.01% | 4596 |
|
|
2025
Q3 | $576 | Buy |
136
+94
| +224% | +$354 | ﹤0.01% | 5693 |
|
|
2025
Q2 | $89 | Sell |
42
-6,565
| -99% | -$9.82K | ﹤0.01% | 5519 |
|
|
2025
Q1 | $8.06K | Sell |
6,607
-9,467
| -59% | -$13.3K | ﹤0.01% | 5226 |
|
|
2024
Q4 | $20.7K | Buy |
16,074
+1,330
| +9% | +$3.19K | ﹤0.01% | 5262 |
|
|
2024
Q3 | $40.5K | Buy |
14,744
+10,259
| +229% | +$25.2K | ﹤0.01% | 5067 |
|
|
2024
Q2 | $10.1K | Buy |
+4,485
| New | +$13.6K | ﹤0.01% | 5140 |
|
|
2024
Q1 | – | Sell |
-10,650
| Closed | -$17.7K | – | 5717 |
|
|
2023
Q4 | $17.7K | Buy |
+10,650
| New | +$20.7K | ﹤0.01% | 5029 |
|
|
2021
Q3 | – | Sell |
-557
| Closed | -$2K | – | 5969 |
|
|
2021
Q2 | $2K | Sell |
557
-1,905
| -77% | -$6.78K | ﹤0.01% | 5974 |
|
|
2021
Q1 | $5K | Sell |
2,462
-4,992
| -67% | -$11.2K | ﹤0.01% | 5886 |
|
|
2020
Q4 | $17K | Buy |
7,454
+5,667
| +317% | +$14.9K | ﹤0.01% | 6741 |
|
|
2020
Q3 | $5K | Sell |
1,787
-3,476
| -66% | -$9.73K | ﹤0.01% | 7009 |
|
|
2020
Q2 | $16K | Sell |
5,263
-6,932
| -57% | -$17.4K | ﹤0.01% | 6773 |
|
|
2020
Q1 | $24K | Buy |
12,195
+4,166
| +52% | +$10.1K | ﹤0.01% | 6567 |
|
|
2019
Q4 | $23K | Buy |
8,029
+5,842
| +267% | +$20.3K | ﹤0.01% | 6868 |
|
|
2019
Q3 | $8K | Sell |
2,187
-6,847
| -76% | -$24.7K | ﹤0.01% | 7170 |
|
|
2019
Q2 | $37K | Sell |
9,034
-49,339
| -85% | -$214K | ﹤0.01% | 6722 |
|
|
2019
Q1 | $298K | Buy |
+58,373
| New | +$280K | ﹤0.01% | 4712 |
|
|
2016
Q2 | – | Sell |
-191
| Closed | – | – | 7182 |
|
|
2016
Q1 | $0 | Sell |
191
-1,134
| -86% | -$1.52K | ﹤0.01% | 7543 |
|
|
2015
Q4 | $2K | Buy |
+1,325
| New | +$3.04K | ﹤0.01% | 7259 |
|
|
2015
Q2 | – | Sell |
-1,098
| Closed | -$4K | – | 7595 |
|
|
2015
Q1 | $4K | Sell |
1,098
-2,134
| -66% | -$7.62K | ﹤0.01% | 6773 |
|
|
2014
Q4 | $11K | Buy |
3,232
+1,284
| +66% | +$5.67K | ﹤0.01% | 6447 |
|
|
2014
Q3 | $10K | Buy |
1,948
+1,796
| +1,182% | +$14K | ﹤0.01% | 6269 |
|
|
2014
Q2 | $2K | Sell |
152
-279
| -65% | -$3.47K | ﹤0.01% | 6740 |
|
|
2014
Q1 | $7K | Buy |
431
+195
| +83% | +$2.78K | ﹤0.01% | 6481 |
|
|
2013
Q4 | $2K | Buy |
+236
| New | +$2.18K | ﹤0.01% | 6776 |
|
Other funds holding GALT
WANY
Citigroup's GALT Position: Q2 2026 in Review
Citigroup increased its Galectin Therapeutics (GALT) stake by 0.78% in Q2 2026, buying an estimated $448 and bringing the position to 22,468 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4664.
Citigroup first reported a position in GALT in Q4 2013 and has held it in 28 quarters since. The position peaked at $298K in Q1 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Citigroup held 22,468 shares of Galectin Therapeutics worth $104K as of Q2 2026.
- Citigroup bought 173 Galectin Therapeutics shares in Q2 2026, an estimated $448.
- Galectin Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4664 holding.
- Citigroup first reported a position in Galectin Therapeutics in Q4 2013 and has held it in 28 quarters since.
- Citigroup's Galectin Therapeutics position peaked at $298K in Q1 2019.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.